Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population

PHASE3CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

June 1, 2022

Study Completion Date

June 1, 2022

Conditions
COVID-19
Interventions
DRUG

nirmatrelvir/ritonavir

Tablets 300/100mg, 2 times a day with 12 ±2 hours interval for 5 days

DRUG

Standard of care

The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines' validated at the time of the study

Trial Locations (11)

Unknown

"Regional Budgetary Healthcare Institution Ivanovo Clinical Hospital", Ivanovo

Kirov State Medical University of Ministry of Health of the Russian Federation, Kirov

State Budgetary Healthcare Institution City Clinical Hospital named after S. I. Spasokukotskiy of Moscow Healthcare Department, Moscow

Regional Clinic Hospital of Ryazan, Ryazan

Ryazan State Medical University named after academician I.P. Pavlov of Ministry of Health of the Russian Federation, Ryazan

Avrora MedFort, LLC, Saint Petersburg

OrCli Hospital, LLC, Saint Petersburg

Ogarev Mordova State University of Ministry of Health of the Russian Federation, Saransk

"Regional State Budgetary Healthcare Institution Clinical Hospital No. 1", Smolensk

Smolensk State Medical University of Ministry of Health of the Russian Federation, Smolensk

"State Budgetary Healthcare Institution of the Yaroslavl Oblast Clinical Hospital No.3", Yaroslavl

All Listed Sponsors
collaborator

Sponsor GmbH

OTHER

lead

Promomed, LLC

OTHER

NCT05601167 - Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population | Biotech Hunter | Biotech Hunter